Publikationen der ALS-Forschungsgruppe an der Charité
Elective termination of respiratory therapy in amyotrophic lateral sclerosis
Meyer T, Dullinger JS, Münch C, Keil JP, Hempel E, Rosseau S,
Thalidomide causes sinus bradycardia in ALS
Meyer T, Maier A, Borisow N, Dullinger JS, Splettstösser G, Ohlraun S,
Progressive muscle atrophy. A rarely diagnosed variant of amyotrophic lateral sclerosis
Meyer T, Münch C, van Landeghem FK, Borisow N, Dullinger J, Linke
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD
Münch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ,
Frequency of a tau genotype in amyotrophic lateral sclerosis
Münch C, Prechter F, Xu R, Linke P, Prudlo J, Kuzma M,
Early-onset ALS with long-term survival associated with spastin gene mutation
Meyer T, Schwan A, Dullinger JS, Brocke J, Hoffmann KT, Nolte CH,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis
Fernández-Santiago R, Hoenig S, Lichtner P,
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop
Ludolph AC, Bendotti C, Blaugrund E,
Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect
Niemann S, Joos H, Meyer T,
The role of excitotoxicity in ALS – what is the evidence?
Ludolph AC, Meyer T, Riepe MW.J
Antiglutamate therapy of ALS – which is the next step?
Ludolph AC, Meyer T, Riepe MW.J
Molecular biology findings in amyotrophic lateral sclerosis
Bachus R, Claus A, Meyer T,
